⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10036655 | 1.00 | — | — | |
| SCHEMBL17642451 | 0.89 | — | — | |
| SCHEMBL20370081 | 0.85 | — | — | |
| SCHEMBL25585169 | 0.71 | — | — | |
| SCHEMBL21066175 | 0.69 | — | — | |
| SCHEMBL13817255 | 0.69 | — | — | |
| SCHEMBL13816963 | 0.68 | — | — | |
| SCHEMBL17196648 | 0.67 | — | — | |
| SCHEMBL10036657 | 0.67 | — | — | |
| SCHEMBL15171197 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790493-B2 | MICROMIRs | ROCHE INNOVATION CENTER COPENHAGEN A/S (CH) | 2017-10-17 | — | — | US | disclosed |
| US-20160060627-A1 | Pharmaceutical Composition for Inhibition of Disease-inducing microRNAs | ROCHE INNOVATION CT COPENHAGEN AS (DK) | 2016-03-03 | — | — | US | disclosed |
| US-20150299699-A1 | MICROMIRs | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2015-10-22 | — | — | US | disclosed |
| US-9133455-B2 | Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140329883-A1 | Pharmaceutical Composition Comprising Anti-miRNA Antisense Oligonucleotides | SANTARIS PHARMA A/S (DK) | 2014-11-06 | — | — | US | disclosed |
| US-20140288299-A1 | PROCESS | SANTARIS PHARMA A/S (DK) | 2014-09-25 | — | — | US | disclosed |
| US-8729250-B2 | Antisense oligonucleotides for inhibition of microRNA-21 | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2014-05-20 | — | — | US | disclosed |
| US-20120238618-A1 | Pharmaceutical Composition Comprising Anti-miRNA Antisense Oligonucleotides | SANTARIS PHARMA A/S (DK) | 2012-09-20 | — | — | US | disclosed |
| US-8163708-B2 | Pharmaceutical composition comprising anti-mirna antisense oligonucleotide | SANTARIS PHARMA A/S (DK) | 2012-04-24 | — | — | US | disclosed |
| US-20120083596-A1 | Pharmaceutical Composition | SANTARIS PHARMA A/S (DK) | 2012-04-05 | — | — | US | disclosed |
| US-20100286234-A1 | Pharmaceutical Composition Comprising Anti-Mirna Antisense Oligonucleotides | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2010-11-11 | — | — | US | disclosed |
| US-20100004320-A1 | Pharmaceutical Composition | SANTARIS PHARMA A/S (DK) | 2010-01-07 | — | — | US | disclosed |